Chemistry, structure & PK
MT-II is what you get when chemists take the active core of alpha-MSH, swap its weak points for durable ones, and…
The ring that made a fragile hormone into a potent drug
MT-II is what you get when chemists take the active core of alpha-MSH, swap its weak points for durable ones, and clamp the chain into a ring. This unit shows that structure atom group by atom group, then follows the molecule through the body: how it is absorbed, how long it lasts, and what is genuinely unknown about its pharmacokinetics.
Understanding the chemistry explains both why MT-II works at tiny doses and why its real-world behavior, especially from nasal sprays, is far less predictable than vendors imply.
Key terms
The molecule, atom group by atom group
MT-II's formula is Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2: an acetyl cap, a norleucine, and then six building blocks (residues) clamped into a ring by a bridge between Asp and Lys. Click each part of the structure to see what it does and why it was chosen. Three deliberate design changes turn a fragile hormone fragment into a rugged one: the natural hormone is described as too unstable in vivo to be used as a therapeutic agent.
The dashed bond is the heart of the design: a lactam bridge joining Asp and Lys that locks the chain into a ring. The ring freezes the molecule into the shape receptors recognize. Combined with the norleucine and D-phenylalanine swaps, the result was reported at about 90 times the potency of alpha-MSH, in a lizard skin bioassay. Read that figure for exactly what it is: a whole-skin test in a reptile, not a receptor assay and not a mammal.
AdvancedThe three changes from alpha-MSH, and why each matters
The synthesis literature names all three in one sentence: replacement of the oxidizable L-methionine with isosteric L-norleucine, replacement of L-phenylalanine with its enantiomer D-phenylalanine, and locking of the chain into its biologically active conformation by lactamization. The result is described as a cyclic analogue of alpha-MSH with good metabolic stability and exceptional activity. What that sentence does not say, and what no source here says, is that the changes erased receptor selectivity: MT-II is described as non-selective, but nobody measured its selectivity before or after the redesign.